CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 413 enrolled
Drug / intervention
SYN-004 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02563106
NCT02563106Phase 2Completed

A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection

Theriva Biologics, Inc.·interventional·Posted Sep 29, 2015·Updated Nov 27, 2018

In Brief

A Phase 2 clinical trial evaluating SYN-004 and Placebo for Clostridium Difficile and Clostridium Infections. Completed, enrolled 413 participants across 43 sites in 7 countries.

Detailed Summary

A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in Hospitalized Patients receiving IV ceftriaxone with a Diagnosis of a Lower Respiratory Tract Infection (LRTI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Canada, Hungary, Poland, Romania, Serbia, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 29, 2015
Enrollment StartOct 1, 2015
Primary CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.8 years ago

Interventions

SYN-004drug

Placebodrug